An observational study in Respiratory Syncytial Virus (RSV) Infection, Acute Lower Respiratory Tract Infections and Bronchiolitis, sponsored by Abu Dhabi Health Services Company. Not yet recruiting at 1 site in United Arab Emirates. Per ClinicalTrials.gov, last updated 2025-06-19.
Sponsored by Abu Dhabi Health Services Company · Observational
This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:
This study is designed to analyze the impact of Respiratory Syncytial Virus (RSV) across different age groups. It focuses on how often RSV occurs, who is most at risk, and its long-term and financial effects. The study uses existing hospital records from SEHA facilities between January 2018 and December 2024. This is a retrospective observational study, meaning no new tests or treatments are given. Researchers look at medical records from past patients who were diagnosed with RSV. Anonymized data is collected from SEHA's Electronic Medical Records (EMR) and laboratory systems. Only patients with confirmed RSV infections are included.
2,093 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 300 across 685 observational studies indexed under Infections.
Browse Infections studies →Abu Dhabi Health Services Company is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study includes all patients of any age who have a laboratory-confirmed diagnosis of Respiratory Syncytial Virus (RSV) infection recorded in the SEHA electronic medical records between January 2018 and December 2024. The population spans from newborn infants to elderly adults, including those with underlying medical conditions such as chronic lung disease, heart disease, immunosuppression, and other comorbidities that may influence RSV severity. Both hospitalized patients and those diagnosed in outpatient settings within SEHA healthcare facilities are included. The study aims to represent the full spectrum of RSV disease burden, clinical outcomes, risk factors, long-term health impacts, and healthcare costs across diverse demographic groups in the UAE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This retrospective study includes patients of all ages with confirmed Respiratory Syncytial Virus (RSV) infection from January 2018 to December 2024, categorized into four cohorts: (1) Infants and young children, including those with risk factors such as prematurity, low birth weight, and chronic lung or heart disease; (2) Adults aged 18-64 years with or without comorbidities; (3) Elderly adults aged 65 and older, with focus on severe outcomes and mortality; and (4) High-risk individuals across all age groups with underlying conditions such as asthma, COPD, diabetes, immunosuppression, Down syndrome, or cystic fibrosis. No interventions are administered; the study analyzes existing data to assess RSV burden, ICU admissions, long-term health impacts, and associated healthcare costs.
Burden of RSV Infection Across All Age Groups
Measurement of the incidence of confirmed RSV infections in patients of all ages using SEHA hospital data from January 2018 to December 2024.
Time frame: January 2018 - December 2024
Burden of RSV Infection Across All Age Groups
Measurement of the prevalence of confirmed RSV infections in patients of all ages using SEHA hospital data from January 2018 to December 2024.
Time frame: January 2018 - December 2024
Identification of Risk Factors for Severe RSV Infection
Analysis of clinical, demographic, and comorbidity data to identify key risk factors associated with severe RSV infection outcomes.
Time frame: January 2018 - December 2024
Proportion of Hospital Admissions Due to RSV
Evaluation of the percentage of total hospital admissions attributed to RSV infections.
Time frame: January 2018 - December 2024
ICU Admission Rates for RSV-Infected Patients
Measurement of the proportion of RSV patients requiring ICU care.
Time frame: January 2018 - December 2024
Financial Burden of RSV Infection
Assessment of direct medical costs associated with RSV hospitalization and ICU care.
Time frame: January 2018 - December 2024
Incidence of Recurrent Wheezing and Asthma Diagnosis Following RSV Infection
Evaluation of long-term respiratory complications, specifically: 1. Clinically diagnosed asthma using standardized clinical criteria (e.g., based on ICD-10 codes or physician diagnosis recorded in medical records) 2. Recurrent wheezing episodes, defined as ≥3 wheezing episodes confirmed by clinical examination or parent report within 12 months post-infection, assessed via structured caregiver questionnaires and medical record review.
Time frame: Up to 12 months post-infection
RSV-Associated Mortality Rates
Analysis of death rates among RSV-positive patients, including 30-day mortality post-admission.
Time frame: January 2018 - December 2024
Long-Term Respiratory Outcomes Following RSV Infection
Evaluation of post-RSV respiratory complications such as asthma and recurrent wheezing.
Time frame: Up to 12 months post-infection
Plan to share: No
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abu Dhabi Health Services Company